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Summary	
Prolyl	 oligopeptidase	 (POP),	 a	 serine	 protease	 highly	 expressed	 in	 the	 brain,	 has	
recently	emerged	as	an	enticing	therapeutic	target	for	the	treatment	of	cognitive	and	
neurodegenerative	 disorders.	 However,	 most	 reported	 inhibitors	 suffer	 from	 short	
duration	 of	 action,	 poor	 protease	 selectivity	 and	 low	 blood-brain	 barrier	 (BBB)	
permeability,	 which	 altogether	 limit	 their	 potential	 as	 drugs.	 Here	 we	 describe	 the	
structure-based	 design	 of	 the	 first	 irreversible,	 selective	 and	 brain-permeable	 POP	
inhibitors.	At	low	nanomolar	concentrations,	these	covalent	peptidomimetics	produce	
a	 fast,	 specific	 and	 sustained	 inactivation	 of	 POP,	 both	 in	 vitro	 and	 in	 human	 cells.	
More	 importantly,	 they	are	>1000-fold	selective	against	two	family-related	proteases	
(DPPIV	and	FAP)	and	display	high	BBB	permeability,	as	shown	in	both	lipid	membranes	
and	MDCK	cells.	
Introduction	
As	tools	 for	chemical	biology,	peptides	often	show	low	permeability	across	biological	
barriers	 and	 rapid	 dissociation	 rates,	 two	 factors	 that	 limit	 their	 potential	 to	 target	
intracellular	 proteins	 (Huhn	 et	 al.,	 2016).	 On	 the	 other	 hand,	 small	 molecules	 can	
achieve	higher	potency	and	permeability,	but	they	have	sometimes	proved	insufficient	
for	the	selective	manipulation	of	proteins	that	share	high	analogy	with	other	members	
of	 the	 family,	 such	 as	 kinases	 and	 proteases.	 These	 issues	 have	 stimulated	 research	
(Baillie,	 2016)	 on	 the	 use	 of	 modified	 peptides	 (peptidomimetics)	 as	 an	 alternative	
class	 of	 covalent	 inhibitors	 able	 to	 encompass	 two	 main	 components:	 i)	 better	
selectivity,	 by	 retaining	 the	main	 features	 of	 peptides—i.e.	 topological	 diversity	 and	
selective	 recognition	 of	 the	 target;	 and	 ii)	 high	 affinity,	 by	 incorporating	 mild	
electrophiles	and	transforming	them	into	covalent	inhibitors.	
Here	 we	 focused	 this	 approach	 on	 the	 inhibition	 of	 prolyl	 oligopeptidase	 (POP),	 an	
81-kDa	cytosolic	protease	that	is	prominently	expressed	in	the	brain	with	the	capacity	
to	hydrolyze	post-proline	bonds	of	small	peptides	(Yoshimoto	et	al.,	1983).	Besides	its	
enzymatic	 function,	 POP	 plays	 important	 roles	 in	 neurogenesis,	 brain	 plasticity	 and	
memory	formation	(Höfling	et	al.,	2016),	although	the	exact	mechanisms	are	not	fully	
known.	Being	a	highly	dynamic	protein	(López	et	al.,	2016),	recent	studies	point	to	the	
involvement	of	POP	in	protein-protein	 interactions	(PPIs)	with	other	partners	such	as	
GAP43,	 a	 protein	 involved	 in	 neuronal	 function	 (Di	 Daniel	 et	 al.,	 2009),	 and	 α-
synuclein,	 an	 intrinsically	 disordered	 protein	 associated	 with	 Parkinson’s	 disease	
(Brandt	et	al.,	2008).	 In	agreement	with	these	findings,	POP	was	shown	to	accelerate	
α-synuclein	 aggregation	 in	 vitro	 and	 in	 cell	 cultures	 (Savolainen	 et	 al.,	 2015),	 thus	
providing	 an	 explanation	 to	 the	 co-localization	 of	 both	 proteins	 in	 the	 brain	 of	
Parkinson’s	disease	(PD)	patients	(Hannula	et	al.,	2013).	
Due	to	 its	 therapeutic	potential,	numerous	compounds	have	been	developed	as	POP	
inhibitors	and	tested	in	preclinical	settings.	Notably,	in	mouse	models	of	PD,	they	have	
been	able	to	accelerate	the	clearance	of	aggregated	α-synuclein	in	the	brain	and,	more	
importantly,	to	restore	the	motor	behavior	that	 is	 impaired	as	a	result	of	the	disease	
(Svarcbahs	 et	 al.,	 2016).	 Also	 recently,	 POP	 inhibitors	 have	 shown	 to	 significantly	
improve	 the	 cognitive	 symptoms	 affected	 by	 schizophrenia	 in	 mice	 (Prades	 et	 al.,	
2017).	Despite	these	promising	results,	POP	inhibitors	have	failed	to	succeed	in	clinical	
trials,	 two	main	 factors	 limiting	 their	 success:	 poor	 selectivity	 against	 related	 prolyl	
peptidases	 (causing	 side	 effects)	 and	 lack	 of	 permeability	 through	 the	 blood-brain	
barrier	 (BBB),	which	 limits	 their	 distribution	 inside	 the	 central	 nervous	 system	 (CNS)	
(López	 et	 al.,	 2013).	 Here	 we	 address	 these	 key	 issues	 through	 the	 design	 and	
characterization	of	a	new	class	of	covalent	POP	inhibitors.	
Structure-guided	design	of	irreversible	POP	inhibitors	
In	 recent	 years,	 numerous	 POP	 inhibitors	 have	 been	 reported	 from	 a	 variety	 of	
scaffolds	such	as	natural	products	(Tarrago	et	al.,	2007),	small	molecules	(Mariaule	et	
al.,	2016),	peptides	and	peptidomimetics	(López	et	al.,	2013).	Some	of	them	feature	C-
terminal	 reactive	 functionalities,	 such	 as	 aldehyde,	 hydroxymethyl	 ketone	 or	 nitrile,	
which	covalently	bind	to	the	hydroxyl	group	of	the	catalytic	serine	(Ser554).	Structure-
activity	 studies	 have	 shown	 that	 these	 covalent	 inhibitors	 are	 more	 potent	 and	
effective	 than	 their	 non-covalent	 analogs	 (Juillerat-Jeanneret,	 2008).	However,	 these	
molecules	form	a	transient	covalent	bond	with	the	enzyme	that	 is	hydrolyzed	after	a	
short	time,	thus	regaining	enzymatic	activity.	Thus,	a	main	goal	in	our	structure-based	
design	 was	 to	 endow	 our	 molecules	 with	 longer	 target	 residence	 times,	 as	 well	 as	
improved	selectivity	and	membrane	permeability.	
The	active	site	of	POP	comprises	three	well-defined	cavities:	S1,	S2	and	S3	(Schechter	
and	Berger,	1967)	that	accommodate	the	peptide	substrate	and	place	the	C-terminal	
prolyl	 carboxylate	 in	 close	 proximity	 to	 the	 catalytic	 Ser554	 (Figure	 1A).	 From	 a	
structural	 perspective,	 S1	 and	 S2	 are	 narrow	 cavities	 that	 tightly	 fit	 around	 the	
substrate	proline	rings	and	account	for	the	high	specificity	of	the	enzyme	(Fülöp	et	al.,	
1998).	 The	 S3	pocket,	 in	 contrast,	 is	 a	 larger	 cavity	 flanked	by	hydrophobic	 residues	
Phe173,	 Met235,	 Cys255,	 Ile591	 and	 Ala594.	 For	 the	 design	 of	 our	 shape-
complementary	inhibitors,	we	have	divided	the	molecules	into	three	parts	(P1,	P2	and	
P3)	and	followed	a	rational	strategy,	considering	some	of	the	best	pharmacophores	for	
potency	and	selectivity,	together	with	a	new	electrophilic	proline	derivative.	
At	position	P3,	POP	inhibitors	often	present	a	single	phenyl	ring,	such	as	the	Cbz	group	
of	ZPP	 (Yoshimoto	et	al.,	1985).	 Instead	of	 the	carbamate	of	 the	Cbz,	a	 three-carbon	
aliphatic	chain—as	in	KYP-2047	(Venäläinen	et	al.,	2006)—has	been	found	optimal	for	
POP	inhibition	(Figure	1A	and	1B).	However,	careful	structural	analysis	reveals	that	the	
S3	pocket	is	large	enough	to	accommodate	bulkier	aromatic	residues,	such	as	Fmoc	(Li	
et	 al.,	 1996),	 which	 can	 provide	 selectivity	 against	 other	 prolyl	 peptidases.	 For	 this	
purpose,	 we	 have	 included	 in	 our	 designs	 a	 fluorinated	 gallic	 acid	 derivative	 (4-
(benzyloxy)-3,5-difluorobenzoyl,	or	BdFB),	which	 in	our	hands	provided	not	only	high	
selectivity,	but	also	extended	microsomal	stability	and	high	lipid	permeability		(Giralt	et	
al.,	2014).	At	position	P2,	L-proline	or	close	analogues	are	optimal	for	activity	(López	et	
al.,	2011).		Here,	with	the	aim	to	enhance	the	drug-like	properties	of	our	inhibitors,	we	
have	 further	explored	 the	 introduction	of	 small	 substituents	 (-F,	 -F2,	 -CH3	or	 -CF3)	 at	
position	4	of	the	proline	ring	(Figure	1C).	
Finally,	at	position	P1	we	have	conveniently	replaced	the	C-terminal	carboxylate	of	the	
natural	substrate	with	a	mildly	reactive	electrophile,	such	as	a	sulfonyl	fluoride	moiety.	
Upon	binding,	this	group	is	intended	to	form	a	stable	covalent	bond	with	the	catalytic	
Ser554	 of	 the	 enzyme,	 thus	 blocking	 its	 activity.	 In	 contrast	 to	 other	more	 reactive	
warheads,	 sulfonyl	 fluorides	 have	 an	 adequate	 balance	 of	 biocompatibility,	 aqueous	
stability	and	protein	reactivity	(Narayanan	and	Jones,	2015),	and	have	found	signiﬁcant	
use	as	probes	in	chemical	biology.	Peptidyl	sulfonyl	fluorides,	in	particular,	have	been	
developed	 as	 chymotrypsin	 (Brouwer	 et	 al.,	 2011)	 and	 proteasome	 (Dubiella	 et	 al.,	
2014)	 inhibitors,	 among	 other	 applications,	 showing	 therapeutic	 efficacy	 and	 safety	
when	administered	in	mice	(Tschan	et	al.,	2013).	All	in	all,	with	the	triple	objective	of	
achieving	high	potency,	selectivity	and	CNS	permeability,	we	sought	to	condense	this	
intricate	structure-activity	data	into	a	peptidomimetic	scaffold	that	combines	optimal	
P2	and	P3	moieties	with	a	unique	prolylsulfonyl	fluoride	warhead,	leading	to	a	total	of	
15	potential	inhibitors	(Table	1).	
Special	attention	was	devoted	 to	 those	 inhibitors	bearing	 the	BdFB	P3	group,	as	 this	
moiety	 is	 much	 bulkier	 than	 the	 gold	 standards	 Cbz	 and	 phenylpropyl.	 However,	
covalent	docking	calculations	revealed	that	these	compounds	can	adopt	a	very	similar	
pose	to	that	reported	for	reversible	inhibitors	ZPP	and	KYP-2047	(Figure	3A)	(Kaszuba	
et	al.,	2012).	As	a	differential	trait,	the	larger	fluorinated	BdFB	moiety	is	able	to	occupy	
most	of	the	S3	cavity,	resulting	in	extended	π-π	contacts	with	F173	and	W595	of	POP.	
On	 the	 other	 hand,	 the	 sulfonyl	 group	 at	 position	 P1,	 despite	 being	 larger	 than	 the	
natural	 amide,	 is	 well	 fitted	 between	 Asn555	 and	 His680,	 and	 provides	 an	 optimal	
binding	geometry	towards	Ser554.	The	flexible	methylene	group	connecting	the	sulfur	
atom	to	the	pyrrolidine	ring	also	facilitates	the	accommodation	of	the	electrophile	 in	
front	of	the	Ser554	side	chain,	thus	enabling	the	covalent	binding	to	occur.	
Sequential	synthesis	yields	highly	potent	POP	inhibitors	
The	synthesis	of	 the	proline	warhead	was	accomplished	by	 starting	 from	the	natural	
precursor	L-prolinol	(Figure	S1A).	The	hydroxyl	group	was	oxidized	in	two	steps	to	the	
sodium	 sulfonate,	 which	was	 fluorinated	 to	 the	 corresponding	 sulfonyl	 fluoride.	 For	
this	reaction,	the	use	of	XtalFluor-M	(L’heureux	et	al.,	2010)	provided	a	cleaner	crude	
product	and	a	higher	yield	(76%)	compared	to	other	fluorinating	agents	such	as	DAST	
and	XtalFluor-E	(13%	and	69%	yield,	respectively).	Once	the	warhead	was	obtained,	a	
divergent	 strategy	 was	 followed	 to	 sequentially	 couple	 the	 respective	 P2	 and	 P3	
groups	(Figure	S1B).	A	single	purification	step,	at	the	end	of	the	synthesis,	afforded	the	
final	compounds	in	a	milligram	scale.	
For	evaluation	and	quantification	of	enzyme	inhibition,	a	fluorometric	assay	was	set	up	
using	recombinant	human	POP.	To	allow	for	comparison,	IC50	values	were	determined	
at	 regular	 time	 points	 during	 the	 linear	 phase	 of	 the	 inhibition	 process	 (Figure	 S2).	
Although	 dependent	 on	 the	 preincubation	 time,	 IC50	 values	 are	 a	 useful	 metric	 to	
compare	the	potency	of	a	given	set	of	inhibitors,	since	their	full	kinetic	characterization	
(see	 below)	 is	 more	 laborious	 and	 time-consuming.	 As	 expected	 from	 the	 rational	
design,	 all	 molecules	 had	 strong	 potencies	 in	 the	 low	 nanomolar	 range	 (Table	 1).	
Derivatization	 of	 position	 4	 of	 the	 P2	 proline	 ring	 (R1,	 R2),	 meant	 to	 enhance	 the	
selectivity	and	membrane	permeability	of	the	inhibitors,	was	well-tolerated	(inhibitors	
11	and	18).	Notably,	the	BdFB	moiety	used	at	P3	resulted	in	highly	potent	compounds	
(17-20).	
Sulfonyl	fluoride	peptidomimetics	show	high	BBB	permeability	
In	addition	to	potency,	 it	 is	 imperative	that	POP	inhibitors	cross	the	BBB	to	enter	the	
brain	 tissue,	 a	 criterion	 that	 peptidomimetic	 drugs	 often	 fail	 to	 meet	 (López	 et	 al.,	
2013).	 This	 is	 not	 surprising	 given	 that	 the	 BBB—a	 highly	 specialized	 and	 complex	
vascular	 system—prevents	 most	 (>98%)	 drugs	 from	 reaching	 the	 CNS	 (Pardridge,	
2005).	To	address	this	issue,	we	studied	the	transport	of	our	compounds	in	the	PAMPA	
assay,	in	which	a	lipid	brain	extract	mimics	the	composition	of	the	BBB,	resulting	in	a	
convenient	method	to	evaluate	the	transport	of	compounds	by	passive	diffusion	(Di	et	
al.,	2003).	Reassuringly,	high	permeability	values	were	obtained	for	all	three	families	of	
compounds	 (Pe	>	10-5	cm	s-1,	 see	Table	1),	 in	 the	same	range	as	propranolol,	a	highly	
permeable	 CNS-active	 drug	 used	 as	 positive	 control.	 In	 particular,	 transport	 was	
increased	 upon	 fluorination	 of	 the	 P2	 proline	 ring;	 in	 contrast,	 the	 introduction	 of	
lipophilic	 groups	 (CH3	 and	 CF3)	 led	 to	membrane	 retention	 and	 a	 slight	 decrease	 in	
permeability.	To	further	validate	these	results,	also	taking	the	effect	of	active	transport	
and	 efflux	 pumps	 into	 account,	 we	 evaluated	 the	 absorptive	 transport	 through	 a	
monolayer	of	MDCK	 cells,	which	 is	 a	more	 relevant	model	 for	 the	prediction	of	BBB	
permeability	 (Wang	 et	 al.,	 2005).	 Again,	 all	 inhibitors	 achieved	 excellent	 transport	
rates,	in	some	cases	higher	than	the	FDA-approved	drug	metoprolol	(Figure	2A).	Only	
the	BdFB	compounds	 showed	slightly	 lower	values	due	 to	 retention	 in	 lipids,	 as	also	
shown	in	the	PAMPA.	
High-affinity	covalent	binding	is	not	compromised	by	off-target	effects	
In	 addition	 to	 POP,	 the	 S9	 family	 of	 serine-proteases	 holds	 other	 proline-specific	
peptidases,	 such	 as	 fibroblast	 activation	 protein	 (FAP)	 and	 dipeptidyl	 peptidase	 IV	
(DPPIV),	 which	 also	 hydrolyze	 proline-containing	 peptide	 hormones	 and	
neuropeptides.	While	DPPIV	is	exclusively	an	exopeptidase,	FAP	also	shares	equivalent	
endopeptidase	activity	with	POP.	As	well	as	being	functionally	related,	the	active	sites	
of	these	three	enzymes	share	a	high	structural	 identity,	with	conserved	Arg,	Phe	and	
Tyr	residues	surrounding	the	catalytic	Ser	(Juillerat-Jeanneret,	2008).	Thus,	the	design	
of	 inhibitors	 with	 a	 good	 degree	 of	 selectivity	 between	 these	 enzymes	 has	 proved	
difficult,	 and	 it	 is	 of	 utmost	 importance	 to	 avoid	 cross-reactivity	 and	 undesired	 side	
effects	(Poplawski	et	al.,	2013).	
To	 assess	 the	 off-target	 reactivity	 of	 our	 compounds,	 three	 class-representative	
inhibitors	(8,	13	and	18)	were	screened	against	FAP	and	DPPIV,	at	concentrations	up	to	
50	µM	(~50,000-fold	the	POP	IC50).	 In	this	assay,	a	remarkable	 level	of	selectivity	was	
found	for	all	three	families	(Table	S1).	Even	at	the	highest	concentration	of	 inhibitors	
(50	 µM),	 catalytic	 activities	 >	 70%	were	 observed	 in	 all	 cases	 for	 FAP	 and	DPPIV.	 In	
particular,	 inhibitor	 18	 had	 a	 marginal	 inhibitory	 effect	 (below	 20%)	 on	 the	 closely	
related	 FAP	 protease.	 At	 lower	 concentrations—in	 the	 POP	 IC50	 range—these	
compounds	 were	 able	 to	 fully	 discriminate	 between	 the	 different	 proline-specific	
peptidases.	 This	 high	 specificity	 fulfills	 a	 main	 requirement	 for	 the	 selective	 and	
covalent	modulation	of	the	POP	enzyme.	
Binding	is	fast,	irreversible	and	specific	for	the	catalytic	Ser	of	POP	
Considering	 the	 previous	 results,	 we	 selected	 inhibitor	 18—having	 a	 suitable	
pharmacological	profile	and	a	more	 innovative	scaffold—for	 further	characterization.	
First,	we	 studied	 the	 inhibition	mechanism	of	 POP	by	 the	 sulfonyl	 fluoride	warhead.	
From	 a	 kinetic	 perspective,	 covalent	 drugs	 block	 their	 targets	 in	 a	 two-step	 fashion	
(Singh	et	 al.,	 2011).	 Initially,	 the	 inhibitor	 associates	 via	 non-covalent	 interactions	 to	
the	target	enzyme—a	process	defined	by	Ki—and	afterwards	the	nucleophilic	attack	by	
the	protein	takes	place,	giving	rise	to	the	inhibited	complex—defined	by	k2	(Figure	2B).	
In	 those	 cases	 in	which	 the	 inhibition	 is	 effectively	 irreversible,	k-2	will	 essentially	be	
zero,	and,	 if	 allowed	sufficient	 time,	 the	binding	 reaction	will	proceed	 to	completion	
rather	 to	 equilibrium.	 In	 order	 to	 confirm	 that	 the	 inhibitory	 mechanism	 was	
irreversible,	compound	18	was	subjected	to	a	complete	kinetic	profiling	(Figure	2B).	
In	 this	 experiment,	 an	 exponential	 decay	 in	 enzyme	 activity,	 dependent	 on	 the	
preincubation	 time,	 was	 observed,	 thus	 confirming	 the	 irreversible	 nature	 of	 POP	
inhibition.	 In	 the	context	of	 irreversible	binding,	 inhibitor	potency	and	selectivity	can	
be	governed	by	the	initial	non-covalent	binding	to	the	enzyme	(Ki),	by	the	subsequent	
bonding	step	(k2),	or	by	both	of	them	(k2/Ki).	For	compound	18,	the	k2/Ki	ratio—being	
the	 parameter	 that	 best	 represents	 inhibitory	 potency—was	 2	 ×	 106	 M-1	 s-1,	 thus	
indicating	a	potent	and	fast	inactivation	of	the	enzyme	(Miyahisa	et	al.,	2015).	
Additionally,	 mass	 spectrometry	 analysis	 of	 a	 BrCN-digested	 POP	 sample	 was	
performed	 to	 confirm	 the	 specific	 binding	 of	18	 to	 the	 active	 site.	 In	 this	 assay,	 the	
mass	of	the	peptide	containing	the	catalytic	Ser554	was	increased	by	508	Da,	versus	a	
buffer-treated	 reference	 sample,	which	 indicated	 single	 sulfonylation	of	 the	 Ser	 side	
chain,	 consistent	 with	 a	 1:1	 inhibitor/protein	 ratio	 (Figure	 2C).	 Therefore,	 the	
combination	of	kinetic	and	mass	spectrometry	POP	binding	assays	reinforced	our	initial	
assumption	 of	 covalent	 and	 irreversible	 modification	 of	 the	 enzyme	 through	 the	
prolylsulfonyl	warhead.	
Low-nanomolar	POP	inhibition	in	intact	human	cells	
In	 order	 to	 assess	 the	 activity	 of	 our	 hit	 compound	 in	 a	 biologically	 more	 relevant	
environment,	 human	neuroblastoma	 SH-SY5Y	 cells	were	 treated	with	 inhibitor	18	 at	
concentrations	 ranging	 from	 0.2	 pM	 to	 200	 nM.	 Subsequently,	 POP	 activity	 was	
measured	 on	 intact	 cells	 by	 recording	 the	 release	 of	 fluorescence	 from	 a	 specific	
substrate	 (Z-Gly-Pro-AMC).	Under	 these	 conditions,	 compound	18	was	 able	 to	 reach	
the	cytosol	and	produce	a	fast—10-min	incubation	time—and	strong	inhibition	of	the	
POP	enzyme,	showing	an	IC50	of	1.4	nM	(Figure	3B).	
Collectively,	our	findings	show	how	the	distinct	strengths	of	reversible	and	irreversible	
mechanisms	can	be	combined	to	yield	drug	candidates	with	carefully	tuned	reactivity	
and	 specific	 target	 engagement.	 As	 pursued	 with	 the	 structure-based	 design,	 the	
optimal	 selection	 of	 P2-P3	 groups,	 combined	 with	 a	 novel	 prolylsulfonyl	 fluoride	
warhead,	 yielded	 POP	 inhibitors	 that	were	 not	 only	 highly	 potent	 and	 selective,	 but	
also	CNS-permeable.	By	analogy	with	other	covalent	inhibitors	such	as	ZPP,	the	binding	
of	 these	 compounds	 to	 the	POP	active	 site	may	produce	a	prolonged	modulation	of	
the	 highly	 dynamic	 protein	 conformational	 equilibrium,	 effectively	 stabilizing	 the	
closed	or	 inactive	 state	 of	 the	 enzyme	 (López	 et	 al.,	 2016).	 If	 this	was	 the	 case,	 our	
inhibitors	would	ultimately	abolish	the	deleterious	interactions	of	POP	with	pathogenic	
proteins	 such	 as	 α-synuclein,	 thus	 opening	 the	 door	 for	 new	 treatments	 of	 CNS	
pathologies.	
Significance	
POP	is	a	proteolytic	enzyme	and	partner	in	intracellular	PPIs	that	is	actively	involved	in	
the	 pathogenesis	 of	 several	 cognitive	 disorders	 ranging	 from	 Parkinson’s	 disease	 to	
schizophrenia.	 Thus,	 designing	 efficient	 inhibitors	 able	 to	 reach	 the	 brain	 and	
discriminate	 POP	 from	 other	 proteases	 has	 been	 one	 of	 the	 main	 objectives	 of	
researchers	 in	 the	 field.	However,	most	 reported	drugs	 are	 reversible	 inhibitors	 that	
have	found	limited	in	vivo	application,	mostly	due	to	low	membrane	permeability,	lack	
of	 selectivity	 and	 short	 residence	 times.	 Here,	 we	 report	 the	 design	 of	 shape-
complementary	 targeted	 inhibitors	 that	 exert	 sustained	 POP	 inhibition	 at	 very	 low	
concentrations.	 In	our	bifunctional	molecules,	 the	peptide	backbone	and	 side	 chains	
form	 a	 template	 that	 selectively	 recognizes	 the	 active	 site	 of	 the	 enzyme—thus	
providing	selectivity—while	the	sulfonyl	 fluoride	electrophile	 irreversibly	binds	to	the	
catalytic	 Ser.	 In	 addition	 to	 their	 low-nM	 potency,	 these	 compounds	 were	 >1000x	
selective	 for	 POP	over	 two	 closely	 related	proteases	 (DPPIV	 and	 FAP),	 thus	 ensuring	
low	cross-reactivity.	Notably,	high	permeability	values	were	obtained	 in	both	PAMPA	
and	MDCK	assays,	 a	property	 that	 translates	 into	a	potent	 cellular	 activity,	 as	 it	was	
shown	in	SH-SY5Y	human	cells.	Beyond	their	application	in	the	study	of	the	function	of	
POP	 in	 CNS	 disorders,	 these	 compounds	 pave	 the	 way	 for	 the	 design	 of	 selective	
irreversible	inhibitors	of	other	serine	proteases.	
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Figure	legends	
Figure	1.	Structure-guided	design	of	irreversible	POP	inhibitors.	A)	Crystal	structure	of	
KYP-2047	 bound	 to	 the	 POP	 active	 site	 (PDB	 4an0),	 highlighting	 the	 main	 enzyme	
cavities	 (S1,	 S2	 and	 S3)	 and	 contiguous	 residues.	 B)	 Representative	 examples	 of	
covalent	 POP	 inhibitors.	 C)	 General	 structure	 of	 the	 family	 of	 shape-complementary	
POP	 inhibitors.	 Selected	 P2	 and	 P3	 groups	 are	 combined	 with	 a	 sulfonyl	 fluoride	
electrophile	to	generate	irreversible-binding	peptidomimetics.	
Figure	2.	Sulfonyl	fluoride	peptidomimetics	show	high	BBB	permeability	and	specific	
and	 irreversible	binding	to	 the	POP	catalytic	site.	A)	Apparent	permeability	 (Papp)	of	
compounds	7-20	and	metoprolol	(control)	in	MDCK	cells.	Error	bars	represent	standard	
deviations	 of	 triplicate	 samples.	 B)	 Kinetic	 constants	 that	 define	 a	 covalent	 binding	
process	 (top).	 The	 exponential	 decay	 of	 POP	 activity,	 at	 several	 concentrations	 of	
inhibitor	18,	 is	 represented	versus	 the	pre-incubation	 time	 (left).	The	kobs	plot	 (right)	
yields	the	kinetic	parameters	that	govern	irreversible	binding	(Ki,	k2).	C)	Mass	spectra	
(right)	 and	 deconvoluted	 mass	 (left)	 of	 the	 CNBr-digested	 catalytic	 peptide	 of	 POP,	
showing	selective	covalent	modification	of	Ser554	by	18.	
Figure	 3.	 Inhibitor	 18	 covalently	 binds	 to	 the	 POP	 catalytic	 site	 and	 displays	 low-
nanomolar	activity	 in	human	cells.	A)	A)	Predicted	binding	of	 inhibitor	18	 (structure	
shown	bottom	right)	to	the	POP	catalytic	pocket,	highlighting	the	main	cavities	(S1,	S2	
and	 S3)	 and	 interacting	 residues.	Hydrogen	bonds	 are	 shown	with	 yellow	dashes.	 B)	
POP	activity	in	intact	human	SH-SY5Y	cells	at	different	concentrations	of	18.	Error	bars	
represent	standard	deviations	of	triplicate	samples.	 	
Tables	
Table	 1.	 Structure	 of	 designed	 POP	 inhibitors,	 their	 activity	 and	
permeability	profile.	
	
Id	 R1	 R2	
Yield	
(%)a	
POP	IC50	
(nM)	
Transport	
(%)b	
Retention	
(%)b	
Pe	(10-6	
cm	s-1)b	
7	 H	 H	 75	 1.3	 19.1	 37.1	 11.4	
8	 F	 H	 51	 4.5	 18.8	 19.7	 11.2	
9	 F	 F	 41	 21.2	 24.8	 2.1	 16.3	
10	 H	 CF3	 48	 7.9	 14.0	 40.7	 7.8	
11	 H	 CH3	 62	 0.8	 23.9	 14.2	 15.4	
12	 H	 H	 59	 3.2	 21.5	 29.3	 13.3	
13	 F	 H	 43	 1.9	 20.2	 23.6	 12.2	
14	 F	 F	 28	 2.3	 25.4	 20.4	 16.8	
15	 H	 CF3	 40	 2.1	 21.5	 51.2	 13.3	
16	 H	 CH3	 46	 1.9	 20.3	 57.8	 12.4	
17	 H	 H	 39	 1.8	 25.4	 26.7	 17.2	
18	 F	 H	 26	 0.9	 26.5	 34.0	 17.9	
19	 F	 F	 18	 1.7	 15.3	 62.3	 8.7	
20	 H	 CH3	 33	 1.2	 19.6	 51.4	 11.8	
KYP-2047	 	 3.9	 13.3	 0.6	 7.3	
aIsolated	 yields	 of	 the	 coupling	 reactions.	 bTransport,	 retention	 and	
permeability	 parameters	 obtained	 in	 the	 PAMPA	 assay.	 Data	 represent	
mean	values	(n=3).	
	
	 	
Contact	for	reagent	and	resource	sharing	
Further	information	and	requests	for	resources	and	reagents	should	be	directed	to	and	
will	be	fulfilled	by	the	Lead	Contact,	Ernest	Giralt	(ernest.giralt@irbbarcelona.org)	
Experimental	model	and	subject	details	
Human	 SH-SY5Y	 cells	 were	 obtained	 from	 the	 American	 Type	 Culture	 Collection	
(ATCC).	 Cells	 were	 cultured	 in	 DMEM-high-glucose	 medium	 containing	 10%	 fetal	
bovine	 serum	 (FBS),	 1%	 glutamine	 and	 1%	 penicillin-streptomycin	 and	 grown	 in	 a	
humidified	incubator	at	37ºC,	5%	CO2.	
Method	details	
General	
Unless	otherwise	stated,	all	solvents	and	chemicals	were	used	as	received.	All	solvent	
mixtures	(eluents)	are	given	in	v/v.	
Analytical	and	preparative	HPLC	
All	 reactions	 were	 monitored	 by	 HPLC	 (Waters	 Alliance	 2695	 equipped	 with	 2487	
photodiode	 array	 detector,	 Sunfire	 C18	 column	 (2.1	 x	 1000	 mm,	 3.5	 µm,	 100	 Å,	
Waters);	 flow	 rate	 =	 1	mL/min;	 solvents	A=0.036%	 trifluoroacetic	 acid	 in	water,	 and	
B=0.045%	trifluoroacetic	acid	in	acetonitrile.	The	reaction	crude	products	were	purified	
by	semi-preparative	HPLC	on	a	Waters	2700	sample	manager	equipped	with	a	Waters	
2487	dual	wavelength	absorbance	detector,	a	Waters	600	controller,	a	Waters	fraction	
collector;	 using	 a	 symmetry	C18	 column	 (100	mm	x	19	mm,	5	µm;	Waters).	 Column	
flow	was	set	at	15	ml/min;	solvents	A=0.1%	trifluoroacetic	acid	 in	water,	and	B=0.1%	
trifluoroacetic	acid	in	acetonitrile.	The	purity	of	all	final	compounds	was	95%	or	higher,	
as	measured	by	HPLC.	
TLC	
Reactions	for	compounds	5-10	were	monitored	by	TLC	analysis	using	Merck	pre-coated	
silica	gel	60	F-254	(0.25	mm)	plates.	Spots	were	visualized	with	UV	light,	ninhydrin,	Cl2-
TDM	 or	 sulfuric	 acid.	 Solvents	 were	 evaporated	 under	 reduced	 pressure	 at	 40°C.	
Column	 chromatography	 was	 performed	 on	 Siliaflash	 P60	 (40-63	 µm)	 from	 Silicycle	
(Canada).		
NMR	
NMR	spectra	were	recorded	on	Varian	Mercury	400,	Agilent	400,	or	Varian	Inova	500	
MHz	 spectrometers,	 using	 CDCl3	 as	 solvent	 at	 25°C.	 Variable	 temperature	 1H	 NMR	
spectra	(400	MHz)	were	recorded	on	a	Varian	S400	spectrometer.	Chemical	shifts	are	
given	in	parts	per	million	(ppm)	(δ	relative	to	residual	solvent	peak	for	1H	and	13C,	or	
relative	to	TMS	(0.00	ppm)	for	compounds	5-10).	Some	of	the	13C	NMR	spectra	were	
recorded	using	the	attached	proton	test	(apt)	pulse	sequence.	Most	of	the	1H	and	13C	
NMR	spectra	contained	additional	peaks,	due	to	the	presence	of	rotamers	and	fluorine	
atoms.	
Chemical	syntheses	
Synthesis	of	the	prolylsulfonyl	fluoride	electrophile	(6)	
Cbz-Pro-ψ[CH2S]-Ac	 (2).	To	a	solution	of	Cbz-Prolinol	 (1,	51.8	g,	220	mmol)	 in	CH2Cl2	
(1.0	L)	was	added	Et3N	(36.8	ml,	262	mmol)	and	the	resulting	solution	was	cooled	in	an	
icebath	for	1	h	under	N2	atmosphere.	Methanesulfonyl	chloride	 (20.4	ml,	264	mmol)	
was	added	dropwise	and	the	mixture	was	stirred	overnight	at	r.t.	Additional	CH2Cl2	(1.0	
L)	was	added	and	the	mixture	was	washed	with	KHSO4	(1.0	M,	3	x	1.0	L),	water	(1.0	L)	
and	 brine.	 The	 organic	 layer	 was	 dried	 with	 Na2SO4	 and	 concentrated	 in	 vacuo,	
affording	the	mesylate	as	a	yellow	oil	 (69.6	g,	220	mmol,	quantitative).	The	mesylate	
was	 not	 stored,	 but	 used	 directly	 in	 the	 reaction	 with	 in	 situ	 generated	 cesium	
thioacetate.	To	this	end,	thioacetic	acid	(23.4	mL,	332	mmol,	1.5	eq.)	was	added	to	a	
mixture	of	cesium	carbonate	(53.3	g,	164	mmol)	in	DMF	(1.1	L)	under	N2	atmosphere.	
After	 stirring	 for	5	min,	 the	 resulting	 suspension	was	decanted	 to	 the	mesylate.	 The	
flask	was	covered	with	aluminium	foil	and	the	mixture	was	stirred	over	3	nights	at	r.t.	
After	completion,	EtOAc	(2.5	L)	and	water	(1.0	L)	were	added	and	the	water	layer	was	
extracted	with	EtOAc	(0.5	L).	The	combined	organic	 layer	was	washed	with	saturated	
NaHCO3	solution	(1.0	L,	2x),	KHSO4	(1.0	M,	1.0	L,	2x)	and	brine	(300	ml).	After	drying	
(Na2SO4)	 and	 concentration	 in	 vacuo,	 the	 crude	 product	 was	 purified	 by	 column	
chromatography	(EtOAc:	Hex,	1:9),	affording	3	as	a	yellowish	solid	(43.9	g,	150	mmol,	
68%).	
Cbz-Pro-ψ[CH2SO2]-ONa	(3).	To	a	solution	of	thioacetate	2	(43.9	g,	150	mmol)	in	acetic	
acid	(450	mL)	was	added	an	aqueous	hydrogen	peroxide	solution	(150	mL,	30%	w/w)	
and	 the	 mixture	 was	 stirred	 overnight	 at	 r.t.	 The	 color	 of	 the	 reaction	 changed	
overnight	 from	 clear	 brown	 to	 clear	 yellow.	 NaOAc.3H2O	 (20.4	 g,	 150	 mmol)	 was	
added	 and	 stirring	 was	 continued	 for	 15	 min.	 DMF	 (500	 mL)	 was	 added	 and	 the	
solution	 was	 concentrated	 in	 vacuo	 to	 approximately	 half	 of	 its	 volume.	 Another	
portion	of	DMF	(500	mL)	was	added	and	evaporated	again	to	about	one	third	of	 the	
volume.	The	addition	and	evaporation	of	DMF	was	 repeated	until	no	more	peroxide	
was	 detected	 in	 the	 receiver	 flask	 with	 KI/starch	 paper.	 The	 mixture	 was	 then	
concentrated	 completely,	 and	 water	 (1.0	 L)	 and	 CH2Cl2	 (500	mL)	 were	 added,	 after	
which	the	aqueous	layer	was	washed	once	with	CH2Cl2	(500	mL).	Lyophilization	of	the	
water	layer	afforded	3	as	a	white	solid	(47.6	g,	145	mmol,	97%).	
Cbz-Pro-ψ[CH2SO2]-F	 (5).	 To	 a	 suspension	 of	 Cbz-Pro-ψ[CH2SO2]-ONa	 (3,	 9.64	 g,	 30	
mmol)	in	CH2Cl2	(600	mL)	was	added	was	XtalFluor-M	(7,	13.2	g,	54.3	mmol),	under	N2	
atmosphere.	After	addition	of	Et3N.3HF	(212	µL,	1.30	mmol),	the	mixture	was	refluxed	
for	 17	 h	 with	 the	 condenser	 fitted	 with	 a	 drying	 tube.	 Unreacted	 XtalFluor-M	 was	
quenched	 by	 addition	 of	 silica	 gel	 (approximately	 20	 g)	 and	 stirring	 for	 5	min.	 After	
filtration,	 the	mixture	was	concentrated	 in	vacuo	and	re-dissolved	 in	EtOAc	 (400	mL)	
and	water	 (100	mL).	 After	 separation,	 the	 organic	 layer	was	 directly	 dried	 (Na2SO4),	
concentrated	to	dryness,	and	loaded	(dissolved	in	CH2Cl2)	on	a	silica	gel	column.	After	
elution	(eluent:	CH2Cl2)	using	slight	pressure	(balloon),	sulfonyl	fluoride	5	was	obtained	
as	a	white	solid	(6.89	g,	22.9	mmol,	76%).	
HCl.H-Pro-ψ[CH2SO2]-F	(6).	To	a	solution	of	sulfonyl	 fluoride	5	 (6.89	g,	22.9	mmol)	 in	
dichloromethane	(230	mL)	was	added	a	solution	of	HBr	 in	acetic	acid	(33%,	138	mL).	
After	stirring	at	r.t.	for	30	min,	the	solvents	were	removed	 in	vacuo.	The	residue	was	
dissolved	in	H2O	(230	mL)	and	washed	with	EtOAc	(2	x	200	mL).	Dowex	2x8	(13.8	g,	Cl-
form)	 was	 then	 added.	 After	 stirring	 for	 5	 min	 at	 r.t.,	 the	 resin	 was	 filtered	 off.	
Lyophilization	of	the	filtrate	afforded	HCl-salt	6	as	an	off-white	solid	(4.2	g,	20.6	mmol,	
90%).	
Synthesis	of	the	final	POP	inhibitors	
General	 Procedure	 for	 the	 Synthesis	 of	 Intermediates	 23-27.	 Benzylchloroformate	
(1.1	 eq.,	 0.13	mmol)	was	 added	dropwise	 to	 a	 stirred	 solution	 of	 the	 corresponding	
proline	analog	(1	eq.,	0.12	mmol)	and	NaHCO3	(2.5	eq.,	0.3	mmol)	in	water/THF	(1:1,	1	
mL)	at	0°C.	The	reaction	was	stirred	for	30	min	at	0°C	and	for	5	h	at	r.t.	The	solution	
was	acidified	with	1M	HCl	aqueous	solution	and	extracted	with	AcOEt	(3	x	10	mL).	The	
combined	 organic	 layer	was	washed	with	 brine	 (20	mL),	 dried	 over	MgSO4,	 filtered,	
and	 evaporated.	 Crude	 products	 were	 used	 in	 the	 next	 step	 without	 further	
purification.	
General	 Procedure	 for	 the	 Synthesis	 of	 Intermediates	 28-36.	 4-(benzyloxy)-3,5-
difluorobenzoic	 acid	 was	 obtained	 as	 previously	 described	 (Giralt	 et	 al.,	 2014).	 4-
phenylbutanoic	acid	or	4-(benzyloxy)-3,5-difluorobenzoic	acid	(1	eq.,	0.12	mmol)	were	
stirred	 at	 r.t.	 in	 anhydrous	 toluene	 (1	mL)	 for	 10	min.	 Oxalyl	 chloride	 (1.5	 eq.,	 0.18	
mmol)	 was	 added,	 and	 the	 reaction	 was	 stirred	 at	 50°C	 for	 1.5	 h.	 The	 solvent	 was	
removed	 in	vacuo	and	the	resulting	crude	product	was	redissolved	in	anhydrous	THF.	
DIPEA	 (2	 eq.,	 41.8	 µL)	 and	 the	 corresponding	 proline	 (1	 eq.,	 0.12	mmol)	was	 added	
neat	at	0°C.	The	reaction	was	stirred	at	0°C	for	1	h	and	at	r.t.	for	3	h.	The	mixture	was	
concentrated	in	vacuo,	redissolved	in	water	(3	mL),	and	acidified	with	1M	HCl	aqueous	
solution.	The	aqueous	 solution	was	extracted	with	AcOEt	 (3	 x	10	mL);	 the	combined	
organic	 layer	 was	 washed	 with	 brine	 (20	 mL),	 dried	 over	 MgSO4,	 filtered,	 and	
evaporated.	Crude	products	were	used	in	the	next	step	without	further	purification.	
General	 Procedure	 for	 L-prolylmethanesulfonyl	 Fluoride	 Coupling.	 HATU	 (1.1	 eq.,	
0.13	 mmol)	 and	 DIPEA	 (2	 eq.,	 0.24	 mmol)	 were	 added	 to	 a	 solution	 of	 the	
corresponding	intermediate	23-36	(1	eq.,	0.12	mmol)	in	DCM	(1	mL).	After	5	min,	neat	
(S)-pyrrolidin-2-ylmethanesulfonyl	 fluoride	 (HCl	salt	6	or	TFA	salt	22)	was	added,	and	
the	mixture	was	stirred	for	3	h	at	r.t.	The	reaction	mixture	was	diluted	with	DCM	(10	
mL),	and	5%	KHCO3	aqueous	solution	was	added	(10	mL).	The	organic	layer	was	then	
dried	 over	 MgSO4,	 filtered,	 and	 evaporated	 in	 vacuo.	 The	 crude	 product	 was	
redissolved	in	2:8	water/acetonitrile	and	purified	by	semi-preparative	HPLC.	
Covalent	docking	of	the	POP	inhibitors	
In	order	to	assess	the	potential	binding	of	our	compounds	to	POP	and	to	study	the	key	
interactions	 within	 the	 catalytic	 site,	 we	 applied	 the	 docking	 software	 CovDock	 to	
predict	 the	 position	 of	 covalently	 bound	 18	 in	 the	 POP	 active	 site.	 As	 no	 crystal	
structure	of	human	POP	has	been	elucidated	to	date,	porcine	POP,	which	shares	97%	
identity	 with	 the	 human	 form,	 was	 used	 for	 the	 docking	 experiment	 (PDB	 code:	
2XDW).	After	 docking,	 a	 short	minimization	of	 the	 complex	was	performed,	 and	 the	
top	 20	 results	 were	 ranked.	 In	 its	 lowest	 energy	 conformation,	 18	 adopted	 a	 very	
similar	conformation	to	that	reported	for	ligands	ZPP	and	KYP-2047	co-crystalized	with	
POP.	
POP	activity	assays	
POP	 was	 obtained	 by	 expression	 in	 E.	 coli	 and	 affinity	 purification	 as	 reported	
previously	 (Tarragó	et	 al.,	 2006).	 POP	activity	was	determined	 following	 the	method	
described	by	Toide	and	coworkers	(Toide	et	al.,	1995).	The	reactions	were	performed	
in	 96-well	 microplates,	 thereby	 allowing	 the	 simultaneous	 monitoring	 of	 multiple	
reactions.	For	each	 reaction,	 the	activity	buffer	 (137	µL,	100	mM	of	Na/K	phosphate	
buffer,	pH	8.0)	was	pre-incubated	 for	15	min	at	37ºC	with	POP	 (5	nM)	and	with	 the	
corresponding	 inhibitor	 solution	 (3	 µL).	 Stock	 solutions	 at	 a	 range	 of	 inhibitor	
concentrations	(typically	1	nM	to	5	mM)	were	prepared	in	DMSO.	After	pre-incubation,	
ZGP-AMC	(N-benzyloxycarbonyl-Gly-Pro-methylcoumarinyl-7-amide,	10	µL,	450	µM	in	
40%	of	1,4-dioxane)	was	added,	and	the	reaction	was	monitored	at	the	fluorimeter	at	
37ºC	 .	The	formation	of	AMC	was	measured	fluorimetrically	 (excitation	and	emission	
wavelengths	were	360/40	and	485/20	nm,	respectively).	For	each	sample,	a	negative	
control	containing	3	µL	of	the	sample	in	DMSO,	10	µL	of	ZGP-AMC	solution	and	137	µL	
of	activity	buffer	were	added	into	the	well	plate.	The	positive	control	of	the	reaction	
consisted	of	 3	 µL	 of	DMSO,	 10	µL	 of	 ZGP-AMC	 solution	 and	 137	µL	 of	 5	 nM	POP	 in	
activity	buffer.		
For	 the	 kinetic	 determination	 of	 compound	 18,	 the	 same	methodology	was	 applied	
using	 a	 range	 of	 inhibitor	 concentrations	 (1	 to	 100	 nM)	 and	 several	 preincubation	
times	(0	to	60	min).	Then,	fluorogenic	substrate	ZGP-AMC	was	added	and	fluorescence	
was	 read	 after	 30	 minutes.	 The	 fitting	 of	 the	 data	 and	 calculation	 of	 the	 kinetic	
parameters	was	performed	as	shown	in	Figure	2.	
Mass	spectrometry	assays	
Exact	 mass	 determination	 was	 performed	 on	 a	 LTQ-FT	 Ultra	 instrument	 (Thermo	
Scientific)	by	direct	 infusion	of	sample	(1	µM	concentration	 in	1:1	water/acetonitrile,	
0.1%	 formic	 acid)	 through	 a	 nanoESI	 chip;	 detection	method	 scan	 (150-2000	 a.m.u.	
range).	
For	the	detection	of	inhibitor	18	bound	to	the	catalytic	site,	a	POP	sample	(130	µL,	20	
µM	in	100	mM	of	Na/K	phosphate	buffer,	pH	8.0)	was	incubated	with	3	equivalents	of	
18	at	 25ºC	 during	 1	 h.	 The	 sample	was	 lyophilized,	 resuspended	 in	 100	µL	 of	water	
containing	40%	formic	acid	and	0.25	M	cyanogen	bromide	and	digested	in	darkness	for	
16	 h	 at	 25ºC.	 Samples	 were	 desalted	 on	 a	 PolyLC	 C4	 column	 and	 eluted	 with	 95%	
acetonitrile	 in	 1%	 formic	 acid.	 The	 samples	 were	 dried	 in	 a	 vacuum	 centrifuge	 and	
reconstituted	in	50	μL	of	water/acetonitrile	(1:1)	containing	1%	formic	acid,	and	were	
directly	infused	on	an	LTQ-FT	Ultra	instrument	(Thermo	Scientific).		
Cell	activity	assays	
Human	 SH-SY5Y	 cells	 (on	 passage	 15)	 were	 seeded	 (5000	 cells	 per	 well)	 in	 a	
fluorescence	96-well	 plate	 suitable	 for	 cell	 culture.	After	72	h	of	 incubation	at	37ºC,	
cells	 reached	 90-100%	 confluence.	 Cells	 were	 washed	 with	 PBS	 and	 treated	 with	
different	concentrations	of	compound	18	 (0.2	 to	200	nM)	 in	140	µL	of	PBS.	After	10	
min	 of	 pre-incubation	 time,	 ZGP-AMC	 (10	 µL,	 150	 µM	 in	 40%	 of	 1,4-dioxane)	 was	
added,	and	the	reaction	was	monitored	at	 the	 fluorimeter	at	37ºC.	The	formation	of	
AMC	was	measured	fluorimetrically	(excitation	and	emission	wavelengths	were	360/40	
and	 485/20	 nm,	 respectively).	 Triplicates	 for	 each	 concentration,	 as	 well	 as	 blanks,	
were	 included.	Fluorescence	values	during	the	 linear	 time	of	 the	 inhibition	 (typically,	
30	min)	were	determined	and	the	IC50	values	were	then	calculated.	
Selectivity	versus	FAP	
To	 determine	 the	 activity	 of	 FAP	 in	 the	 presence	 of	 the	 inhibitors,	 reactions	 were	
performed	in	96-well	microplates.	For	each	reaction,	the	activity	buffer	(129.5	µL,	100	
mM	 of	 Na/K	 phosphate	 buffer,	 pH	 8.0)	 was	 pre-incubated	 for	 15	min	 at	 37ºC	 with	
recombinant	 human	 FAP	 (7.5	 µL,	 0.57	 nM)	 and	 with	 the	 corresponding	 inhibitor	
solution	(3	µL).	Stock	solutions	at	a	range	of	inhibitor	concentrations	were	prepared	in	
DMSO.	 After	 pre-incubation,	 ZGP-AMC	 (10	 µL,	 1.5	 mM	 in	 40%	 of	 1,4-dioxane)	 was	
added,	 and	 the	 reaction	 was	 incubated	 for	 60	 min	 at	 37ºC	 in	 a	 fluorimeter.	 The	
formation	 of	 AMC	 was	 monitored	 fluorimetrically	 (excitation	 and	 emission	
wavelengths	were	360/40	and	485/20	nm,	respectively).		For	each	sample,	a	negative	
control	containing	3	µL	of	the	sample	in	DMSO,	10	µL	of	ZGP-AMC	solution,	and	129.5	
µL	of	activity	buffer	were	added	to	the	well	plate.	The	positive	control	of	the	reaction	
consisted	of	3	µL	of	DMSO,	10	µL	of	ZGP-AMC	solution,	and	137	µL	of	0.57	nM	FAP	in	
activity	buffer.	Triplicates	for	each	condition	were	included.	Fluorescence	values	versus	
time	 were	 represented	 and	 the	 lineal	 time	 was	 determined.	 Afterwards,	 the	
percentage	of	FAP	 inhibition	was	calculated	at	point	concentrations	of	 inhibitors	 (50,	
10,	5	and	1	µM)	by	comparing	the	fluorescence	intensity	of	the	sample	with	that	of	the	
blank.	
Selectivity	versus	DPPIV	
The	ectodomain	(residues	39-766)	of	dipeptidyl	peptidase-IV	(DPPIV)	was	obtained	by	
expression	 in	 Sf9	 insect	 cells	 using	 the	 Baculovirus	 technique.	 DPPIV	 activity	 was	
determined	 following	 the	 method	 previously	 described	 (Checler	 et	 al.,	 1985).	 The	
reactions	were	performed	in	96-well	microplates.	For	each	reaction,	the	activity	buffer	
(132	µL,	50	mM	Tris,	1	M	NaCl,	1	mg/mL	BSA,	pH	7.5)	was	pre-incubated	for	15	min	at	
37ºC	with	recombinant	human	DPPIV	(5	µL,	12.3	µg/mL)	and	with	the	corresponding	
inhibitor	 solution	 (3	 µL).	 Stock	 solutions	 at	 a	 range	 of	 inhibitor	 concentrations	were	
prepared	 in	 DMSO.	 After	 pre-incubation,	 GP-AMC	 (H-Gly-Pro-methylcoumarinyl-7-
amide,	 10	 µL,	 0.75	 mM	 in	 40%	 of	 1,4-dioxane)	 was	 added,	 and	 the	 reaction	 was	
incubated	 for	20	min	at	37ºC.	The	 formation	of	AMC	was	monitored	 fluorimetrically	
every	 5	 min	 (excitation	 and	 emission	 wavelengths	 were	 360/40	 and	 485/20	 nm,	
respectively).	 For	 each	 sample,	 a	 negative	 control	 containing	 3	 µL	 of	 the	 sample	 in	
DMSO,	10	µL	of	GP-AMC	solution	and	132	µL	of	activity	buffer	were	added	to	the	well	
plate.	The	positive	control	of	the	reaction	consisted	of	3	µL	of	DMSO,	10	µL	of	GP-AMC	
solution	 and	 132	 µL	 of	 12.3	 µg/mL	 DPPIV	 in	 activity	 buffer.	 Triplicates	 for	 each	
condition	were	 included.	 Fluorescence	 values	 versus	 time	were	 represented	and	 the	
lineal	 time	 was	 determined.	 Afterwards,	 the	 percentage	 of	 DPPIV	 inhibition	 was	
calculated	at	point	concentrations	of	inhibitors	(50,	10,	5	and	1	µM)	by	comparing	the	
fluorescence	intensity	of	the	sample	with	that	of	the	blank.	
Parallel	Artificial	Membrane	Permeability	Assay	(PAMPA)	
The	PAMPA	was	used	to	determine	the	capacity	of	the	compounds	to	cross	the	BBB	by	
passive	 diffusion.	 The	 effective	 permeability	 of	 the	 compounds	was	measured	 at	 an	
initial	 concentration	 of	 200	 μM.	 The	 PAMPA	 buffer	 solution	 was	 prepared	 from	 a	
concentrated	one	and	the	pH	was	adjusted	to	6.8.	1-propanol	 (20%)	was	added	as	a	
cosolvent	 to	 the	 buffer	 solution.	 Stock	 solutions	 of	 all	 compounds	 at	 20	 mM	
concentration	 were	 prepared	 in	 DMSO,	 and	 1:100	 dilution	 with	 PAMPA	 buffer	 was	
performed	in	each	case.	For	the	assays,	the	PAMPA	sandwich	was	disenabled,	and	the	
donor	wells	were	filled	with	200	μL	of	the	compound	solution	of	interest.	Before	this,	
the	 polycarbonate	 filter	 of	 the	membrane	was	 coated	with	 4	 μL	 of	 the	 commercial	
mixture	of	phospholipids.	The	acceptor	compartments	were	filled	with	PAMPA	buffer	
containing	1%	DMSO	(200	μL).	After	this,	both	plates	were	reassembled.	The	PAMPA	
sandwich	was	 incubated	 in	humidity-saturated	chamber	for	4	h	with	orbital	agitation	
at	100	rpm.	After	this	time,	the	donor	and	acceptor	wells	were	analyzed	and	quantified	
by	HPLC	at	λ=220	nm.	Propranolol	was	used	as	a	positive	control.	Experiments	were	
performed	in	triplicate.	The	phospholipid	mixture	used	was	a	porcine	polar	brain	lipid	
extract.	Composition:	phosphatidylcholine	(PC)	12.6%,	phosphatidylethanolamine	(PE)	
33.1%,	phosphatidylserine	(PS)	18.5%,	phosphatidylinositol	(PI)	4.1%,	phosphatidic	acid	
0.8%,	 and	 30.9%	of	 other	 compounds.	 After	 4	 h,	 the	 effective	 permeability	 (Pe),	 the	
standard	 parameter	 that	 quantifies	 transport	 independently	 of	 time	 and	
concentrations,	was	calculated:	𝑃! = −218.3𝑡  log 1−  2𝐶! 𝑡𝐶!(𝑡!)  x 10!!	
where	 t	 is	 the	 running	 time	 (4	 h),	 CA(t)	 is	 the	 concentration	 of	 compound	 in	 the	
acceptor	well	at	time	t	and	CD(t0)	is	the	concentration	of	compound	in	the	donor	well	
at	t=0	h.	Transport	 (%)	values	were	obtained	by	dividing	the	amount	 in	 the	acceptor	
well	at	time	t,	CA(t),	by	the	amount	in	the	donor	well	at	time	zero,	CD(t0),	multiplied	by	
100.	 Permeability	 was	 considered	 excellent	 when	 values	 were	 >4.0	 ×	 10–6	 cm/s,	
uncertain	between	2.0	×	10–6	and	4.0	×	10–6	cm/s,	and	poor	below	2.0	×	10–6	cm/s	(Di	
et	al.,	2003).	
MDCK	permeability	assay	
A	monolayer	of	MDCK	cells,	already	prepared	in	a	96-well	plate,	was	purchased	from	
ReadyCell,	S.L.	The	Trans-Epithelial	Electrical	Resistance	(TEER)	was	measured	prior	to	
the	 assay	 in	 order	 to	 verify	 the	 integrity	 of	 the	 monolayer.	 Stock	 solutions	 of	 all	
compounds	at	4	mM	concentration	were	prepared	in	DMSO,	and	1:100	dilutions	with	
sterile	HBSS	buffer	(supplemented	with	5	mM	glucose,	pH	7)	were	performed	in	each	
case.	Apical	(donor)	wells	were	filled	with	100	μL	of	the	compound	solution	(40	μM).	
Basal	 (acceptor)	 compartments	were	 filled	with	 PAMPA	buffer	 containing	 1%	DMSO	
(250	μL).	Then,	both	plates	were	reassembled	and	the	multi-well	plate	was	incubated	
for	2h	at	37ºC.	After	this	 time,	the	donor	and	acceptor	wells	were	disassembled	and	
each	analyzed	by	UPLC-MS.	Metoprolol	was	used	as	a	positive	control.	A	Lucifer	Yellow	
paracellular	permeability	assay	was	performed	after	 the	assay	 for	quality	control.	All	
experiments	 were	 performed	 in	 triplicate.	 The	 apparent	 permeability	 for	 each	
compound	was	calculated	using	the	following	equation:	𝑃!"" = 𝑑𝑄 𝑑𝑡𝐶! x A 	
Data	S1.	NMR	spectra	and	mass	spectrometry	characterization	of	 the	described	 final	
compounds	and	intermediates	(related	to	Table	1).	
Quantification	and	statistical	analysis	
In	vitro	experiments	(Figure	2,	3	and	S2)	were	performed	in	triplicate.	For	the	enzyme	
activity	and	cellular	assays,	fluorescence	values	versus	time	were	plotted	and	the	lineal	
time	 was	 identified.	 Afterwards,	 the	 percentage	 of	 inhibition	 at	 each	 concentration	
was	calculated	and	the	results	were	fitted	using	a	four	parameter	log[inhibitor]	versus	
response	and	reported	directly	from	the	GraphPad	Prism	output.	
